GenomeDx's Decipher GRID™ Evaluates New Biomarker for Prostate Cancer, Further Defines Utility of Decipher Prostate Cancer Test

Studies Presented at Society of Urologic Oncology Annual Meeting

02 Dec, 2015, 16:30 ET from GenomeDx Biosciences

SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that data from two separate studies demonstrating the power of its Decipher Genomic Resource Information Database (Decipher GRID™), the world's largest database of genomics expression data in urological cancer. The studies were presented by Ashley Ross, M.D., Ph.D., associate professor of urology and oncology at Johns Hopkins School of Medicine, today at the Society of Urologic Oncology's 16th Annual Meeting, held in Washington, D.C.

In one study, researchers utilized Decipher GRID to investigate the role of the immunomodulatory marker B7H3 in predicting prostate cancer outcomes and its relationship to androgen receptor activity. In 905 patients treated at Johns Hopkins and Mayo Clinic, researchers found that higher B7H3 expression was positively associated with higher Gleason Scores and tumor stage (p<0.01), and higher likelihood of BCR, metastasis and prostate cancer specific mortality (p<0.001). 

In a second study, researchers using Decipher GRID identified 422 patients treated with radical prostatectomy across four institutions who had adverse pathology features following surgery (Mayo Clinic (n=86), Durham VA (n=104), Johns Hopkins Medical Institution (n=114), and Thomas Jefferson University (n=118)).  Patients with high Decipher and CAPRA-S score were more likely to benefit from adjuvant radiation therapy, while patients with low Decipher and CAPRA-S score have a low rate of metastatic events regardless of treatment selection. Researchers analyzed a primary end point of clinical metastasis in men undergoing adjuvant radiation therapy (ART) (n=111), early salvage radiation therapy (SRT) (n=70), delayed SRT (n=83) and no ART/SRT (n=158) for pT3 disease or positive surgical margin. Both CAPRA-S and Decipher had independent predictive value on multivariable analysis for metastatic outcome (both p<0.05).

"Decipher GRID is a powerful database of genomic information on urological cancer, made possible by data sharing of tumor samples from leading medical centers across the country," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "Information gleaned from GRID is improving our understanding of prostate cancer, further validating Decipher and guiding the development of new genomic tests for predicting outcomes at various stages of urological disease."

About Decipher® Prostate Cancer Classifier 
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.

Learn more at www.DecipherTest.com 

About Decipher GRIDTM 
The Decipher Genomic Resource Information Database (Decipher GRID™) is the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GRID unifies a patient's whole genome data with clinical outcomes from thousands of patients evaluated with Decipher®, providing unprecedented data sharing capabilities. Ultimately, GRID will use patient tumor genomic information to better match an individual to a targeted therapy with the highest likelihood of providing a benefit. The Decipher GRID program is rapidly expanding as major cancer centers partner with GenomeDx to access the database to advance their understanding of urologic cancers through the analysis of large amounts of genomic data.

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences 
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRIDTM, the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.

Learn more at www.GenomeDx.com

Media Contact: 
Ian Stone 
Canale Communications 
619-849-5388 
ian@canalecomm.com

 

SOURCE GenomeDx Biosciences



RELATED LINKS

http://www.GenomeDx.com